Publicaciones en colaboración con investigadores/as de Università di Perugia (10)

2023

  1. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline

    Annals of Oncology, Vol. 34, Núm. 5, pp. 452-467

2022

  1. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

    European Journal of Haematology, Vol. 108, Núm. 1, pp. 73-83

  2. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Blood, Vol. 140, Núm. 11, pp. 1229-1253

2021

  1. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 11, pp. 785-798

2020

  1. Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis

    The Lancet Haematology, Vol. 7, Núm. 10, pp. e746-e755

  2. The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis

    Journal of Thrombosis and Haemostasis, Vol. 18, Núm. 8, pp. 1940-1951

2019

  1. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 20, Núm. 6, pp. 781-794

2018

  1. Maintenance Treatment and Survival in Patients with Myeloma: A Systematic Review and Network Meta-analysis

    JAMA Oncology, Vol. 4, Núm. 10, pp. 1389-1397

2015

  1. The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry

    Thrombosis Journal, Vol. 13, Núm. 1

2014

  1. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

    American Journal of Hematology, Vol. 89, Núm. 4, pp. 355-362